GoodRx said that Boehringer will offer both high- and low- concentration versions of the biosimilar at an exclusive cost of $550 per two-pack on the GoodRx website.
The last few months have been difficult for Gilead, with several late-stage failures and development discontinuations. Amid these problems, Merdad Parsey will be stepping down from his CMO role early next year.
Agenus is now looking for alternative pathways to initiate a Phase III trial for BOT/BAL, including potential partnerships.
As the DOJ and SEC look into two of its senior employees, Cassava Sciences’ CEO and one senior vice president have departed the company.
Envision’s latest technological innovation provides a creative response to one of the megatrends reshaping the sector to improve medical affairs decision-making with actionable data-driven insights.
The lawsuit claims that CMS’s plan to include the drug, Xphozah, along with all other oral-only phosphate lowering therapies in the End-Stage Renal Disease Prospective Payment System (ESRD) will “significantly and negatively impact patient choice of and timely access to important medications.”